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Abstract
Many clients who undergo methadone maintenance (MM) treatment for heroin
and other opiate dependence prefer abstinence from methadone. Attempts at methadone
detoxification are often unsuccessful, however, due to distressing physical as well as
psychological symptoms. Outcomes from a MM client who voluntarily participated in an
Acceptance and Commitment Therapy (ACT) – based methadone detoxification program
are presented. The program consisted of a 1-month stabilization and 5-month gradual
methadone dose reduction period, combined with weekly individual ACT sessions. Urine
samples were collected twice weekly to assess for use of illicit drugs. The participant
successfully completed the program and had favorable drug use outcomes during the
course of treatment, and at the one-month and one-year follow-ups. Innovative behavior
therapies, such as ACT, that focus on acceptance of the inevitable distress associated with
opiate withdrawal may improve methadone detoxification outcomes.

KEYWORDS: Acceptance; mindfulness; psychological flexibility; experimental
avoidance; Acceptance and Commitment Therapy; opiate dependence; methadone
detoxification.
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Using Acceptance and Commitment Therapy during Methadone Dose Reduction:
Rationale, Treatment Description, and a Case Report
The burden of illicit opiate use is substantial, including high morbidity and
mortality rates, health care utilization costs, legal involvement, family discord, and lost
productivity (Amato, Davoli, Ferri, Growing, & Perucci, 2004). To date, methadone
maintenance (MM) is the treatment of choice for opiate dependence. Patients typically
enter MM treatment after heroin or other opiate dependence is well-established, with the
average length of stay at any particular clinic being 1-2 years (D’Aunno, Folz-Murphy, &
Lin 1999). Many MM patients transfer from clinic to clinic, however, remaining on
methadone for many years, and, for some, the remainder of their lives. MM is a
successful treatment as it is associated with decreases in client’s illicit drug use and
health risk behaviors, as well as significant improvement in social functioning (Simpson,
Joe, & Bracy, 1982). Yet, MM remains controversial (Magura & Rosenblum, 2001).
Many professionals believe that substituting one addiction for another is not ethically or
therapeutically acceptable. In addition, long-term MM treatment incurs significant
financial burden, restrictions in daily activities, and unpleasant stigma. The majority of
MM clients state a preference for abstinence (e.g., Lenne et al., 2001), and a number of
them request detoxification or attempt to detoxify themselves (Latowsky, 1996).
The primary obstacle, however, lies in the physical and psychological discomfort
accompanying methadone detoxification (Magura & Rosenblum, 2001). Withdrawal
from methadone results in severe and protracted physiological symptoms (e.g., nausea,
diarrhea, bone pain). Methadone withdrawal experiences are reported to be even more
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severe than heroin withdrawal (e.g., Gossop & Strang, 1991), with failure to successfully
taper off methadone being the rule, rather than the exception (Magura & Rosenblum,
2001). Adverse psychological experiences are also deterrents to detoxification. Most
prominent is an intense fear related to experiencing detoxification symptoms (e.g.,
Eklund, Hiltunen, Melin, & Borg, 1997). Long before symptoms are physically present,
anxiety and worry about impending pain and suffering are reported. Consequently,
clients who report detoxification phobia are more likely to stay in MM treatment longer
and make fewer detoxification attempts (Milby et al., 1994). MM clients who have failed
methadone detoxification report that anticipation or fear of intense withdrawal, rather
than actual physical symptoms, was the predominant reason for the discontinuation of
detoxification (Berger & Schwegler, 1973).
Thus, relapse to opiates or other illicit substances and premature termination of
detoxification are the most common outcomes especially when clients undergo rapid
methadone dose reduction in a poorly supervised outpatient setting (Gossop, Marsden,
Stewart, & Treacy, 2001). Many experts, for this reason, advocate for life-long MM
treatment. Methadone detoxification is typically patient-initiated and may only be
recommended to a selected group of clients who have a relatively stable life without the
current use of illicit drugs.
Behavioral strategies, such as systematic desensitization (e.g., Hollands &
Turecek, 1980) and contingency management (e.g., Robles, Stitzer, Strain, Bigelow, &
Silverman, 2002) have been tested to improve detoxification outcomes. These studies
revealed equivocal results (e.g., short-term effects), however. Given the inevitability of
physical and psychological struggles in methadone detoxification, these treatments could
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possibly be made more effective by teaching clients skills to function more effectively
while experiencing these difficulties. In other words, the problem in this context may not
be simply the presence or intensity of detoxification fears and withdrawal symptoms, but
the ways in which individuals act on their distressing psychological experiences.
This line of reasoning overlaps with a contemporary behavioral process purported
to underlie psychopathology, psychological inflexibility (PI; Hayes, Luoma, Bond,
Masuda, & Lillis, 2006). Psychological inflexibility is defined as one’s limited and rigid
behavioral repertoires in the presence of negatively evaluated private events (thoughts,
feelings, bodily sensation, etc), and is the overarching process targeted by Acceptance
and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). According to the
model, the inflexible patterns are due to the domination of unavailing avoidance- and
control-based coping strategies, collectively referred to as experiential avoidance (Hayes
et al., 2006). The domination of these behavioral patterns is thought to suppress valuedirected and constructive behaviors. The ACT model suggests that the primary problem
of negative affect is its function, rather than its existence per se. In other words, these
events are problematic only because they occasion problematic behavior.
Research has shown that PI is linked to a wide range of psychological problems
and functions as a mediator of treatment outcomes (Hayes et al., 2006). Recent studies
suggest that PI may be a key process involved in the methadone detoxification process.
Individuals with chronic opiate use tend to have greater fear of anxiety and anxietyrelated sensation (e.g., Lejuez, Paulson, Daughters, Bornovalova, & Zvolensky, 2006).
Those undergoing MM treatment have less distress tolerance than those who do not have
substance use problems and display limited behavioral repertoires (i.e., predominantly
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avoidance strategies) when experiencing negative affect (Compton, Charuvastra, & Ling,
2001).
Several studies, ranging from case report studies to randomized controlled trials,
have shown promising outcomes with ACT in substance use problems (e.g., Gifford et
al., 2004; Hayes, Wilson, et al., 2004; Twohig, Schoenberger, & Hayes, 2007; Heffner,
Eifert, Parker, Hernandez, & Sperry, 2003) . In one randomized controlled trial (Gifford
et al., 2004), ACT was compared to Nicotine Replacement Therapy. Results revealed that
ACT participants were more likely to remain abstinent at one-year follow-up (35% vs.
10%). The study also showed that smoking-related PI mediated smoking outcomes, while
negative affect and withdrawal symptoms did not. These findings suggest that an
individual’s approach to distress related to smoking cessation, rather than their absolute
level of emotional discomfort or distress, may be a crucial factor contributing to treatment
outcome. ACT components likewise showed considerable promise in a recent pilot study
examining a multicomponent distress tolerance treatment for early lapsing smokers
(Brown et al., 2008).
The impact of ACT on substance use among poly-substance-abusing MM clients
has also been investigated (Hayes, Wilson et al. 2004). Results revealed that compared to
MM treatment alone, the 16-week ACT combined with MM resulted in lower opiate use
(61% vs. 28%) and lower total drug use (50% vs. 12%) at 6-month follow up.
To date, no study has examined whether ACT facilitates methadone
detoxification. We present a case report of an adult MM client who received weekly
individual ACT adjunctive to a 24-week gradual methadone dose reduction program. The
case investigation has three purposes: (1) To illustrate how an ACT model of treatment
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can be applied to methadone detoxification; (2) To evaluate the effect of a 6-month ACTenhanced methadone dose reduction program on treatment completion, opiate use, and
the use of other illicit drugs; (3) To gather preliminary data on the relation between PI
and treatment outcomes. If the ACT model were supported, the client would successfully
complete the program, while showing a reduction in PI.
Case Description
To protect the client’s confidentiality, the identity of the client was altered. The
client was a 57-year-old Hispanic American male with a high school education. He lived
in a house with his second wife and her two teenage daughters in a large Southern US
city. The client also had two biological children, a son and daughter, from his first
marriage. They were now adults and living independently elsewhere. The client’s first
wife died 7 years prior from Hepatitis C contracted through heroin use. Five years after
her death he married his current wife. At the time of intake, the client was employed fulltime at an oil/gas factory.
Intake screening with the Structured Clinical Interview for DSM (SCID: First,
Spitzer, Gibbon, & Williams, 2002) and the Addiction Severity Index (ASI: McLellan,
Luborsky, Woody, & O’Brien, 1980) revealed that the client had a history of dependence
on alcohol (sustained full remission) and opiates (with agonist replacement therapy), and
abuse of cocaine. The client began drinking alcohol during his adolescent years,
eventually drinking 12-24 drinks daily. At age 32, he attended a residential alcohol
treatment program, which resulted in complete abstinence from alcohol thereafter. Many
other substances were used periodically from adolescence through his 40s including
diazepam, barbiturates (20 yrs), marijuana (20 years), amphetamines/ methamphetamine
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(10 years), cocaine (10 years), LSD/glue (3 years). For a period of 17 years he reported
using more than one substance daily. Beginning at age 40, the client began using heroin
almost daily for 10 years and then entered MM treatment. He was at the MM clinic for 7
years prior to voluntarily transferring to our methadone dose reduction program. Over the
last two years the client attempted methadone detoxification at his MM clinic twice
unsuccessfully; each time resuming his original dosing schedule within a few weeks. The
client attributed the discontinuation of detoxification to intense withdrawal symptoms and
emotional distresses. He reported being nervous and jittery and experienced increased
sweating, insomnia, and depression. No other Axis I or II psychiatric disorders were
identified. However, his score on the Beck Depression Inventory-II (BDI-II; Beck, 1996)
was 10, indicating that he experienced slightly elevated levels of depression at the time of
intake.
The client was a highly appropriate candidate for methadone detoxification. He
had a relatively stable life in that he was married, employed, and had been abstinent from
alcohol and other drugs for at least 10 years (intake urine screen was negative for all
substances except methadone). He displayed strong motivation for methadone
detoxification, stating lack of freedom as his major motive. Nevertheless, he reported that
methadone detoxification seemed extremely challenging due to withdrawal symptoms
and previous lack of success. He had a long and extensive substance use history, and thus
his coping seemed to be limited to avoidance and control-oriented strategies, such as
distraction and positive-self talk; strategies intended to escape or eliminate negative
thoughts, feelings, and bodily sensations. Given the apparent deficit of alternative skills,
it was predicted that he would likely report withdrawal symptoms and psychological
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distress relatively early in the course of treatment. His narrow repertoire of coping skills,
however, seemed balanced by his strong self-reported desire to pursue personal values
(e.g., being free).
Setting and Staff
The ACT-enhanced methadone detoxification was conducted in a university
substance abuse research center staffed by interdisciplinary treatment team (e.g., nurses,
psychiatrist, pharmacist, masters-level therapists, principal investigator, and therapist
supervisor). The ACT therapy was conducted by a masters-level therapist with a
cognitive-behavior therapy background who had worked in the field of substance use
treatment for several years. She was trained and supervised in doing ACT by the second
and third authors and on substance abuse treatment issues by the first author.
Assessment
Substance Use. Throughout the course of the dose reduction program, the client’s
substance use and subjective withdrawal experience were measured twice weekly and at
the one-month and one-year follow-up assessments. Substance use was measured using
Qualitative urine toxicology screens for the presence of cocaine, heroin, amphetamines,
barbiturates, benzodiazepines, tetrahydrocannabinol, caffeine, nicotine, and methadone.
Breath alcohol concentration (BAC) in breath samples were also measured using an
alcohol meter (Alco Sensor 3) which detects recent alcohol use.
Subjective Withdrawal Experience. The client’s withdrawal experience was
assessed weekly and at both follow-up time points using the Subjective Opiate
Withdrawal Scale (SOWS; Handelsman, Cochrane, Aronson, Ness, Rubinstein, & Kanof,
1987). The SOWS contains items to rate the intensity of 16 different withdrawal
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symptoms using a scale of 0 (not at all) to 4 (extremely), with greater scores suggesting
greater subjective withdrawal experiences. The SOWS has established psychometric
properties and provides a sensitive measure of withdrawal severity and changes in
withdrawal severity (Gossop, 1990). Interclass correlations assessing test-retest reliability
were significant at the p = .001 level (Handelsman et al., 1987). The SOWS items reflect:
feeling sick, stomach cramps, muscle spasms/twitching, feelings of coldness, heart
pounding/racing, muscle tension/feeling tense, aches and pains, yawning, runny eyes, and
insomnia/sleeping problems.
Negative Affect. The BDI-II (Beck, 1996), one of the most widely used selfreport measures of depression, was administered at pretreatment and at both one-month
and one-year follow-up time points to assess the levels of depression.
The Detoxification Fear Survey Schedule (DFSS-27: Gentile & Milby, 1992) is a
27-item measure of fear of relapse, withdrawal symptoms, and AIDS rated on a Likert
scale. The DFSS has demonstrated adequate internal consistency, ranging from .74 to .96
and good two-week test-retest reliability (r = .77). Based on a sensitivity analysis, a cutoff score of 70 was selected for identifying diagnostically significant and severe
detoxification fear. The DFSS was administered monthly and at one month and one year
follow-up time points.
Psychological Inflexibility. The Acceptance and Action Questionnaire (AAQ;
Hayes, Strosahl, et al., 2004) was administered monthly and at the follow-up time points
to measure level of psychological inflexibility (PI) or inflexible behavior repertoires,
such as experiential avoidance, in the presence of negatively evaluated private events
(thoughts, feelings, bodily sensation, etc). The AAQ (i.e., 9-item vesion) is a 7-point
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Likert scale with adequate internal consistency (alpha of .70; Hayes, Strosahl, et al.,
2004).
Program Overview
Methadone Dose Reduction Schedule
Based on a previous agonist-replacement therapy detoxification study using levoalpha acetyl methadol (LAAM; Grabowski et al., 2005), a 24-week detoxification period
was selected, beginning with a 4-week stabilization phase, in which methadone doses
were adjusted based on client weight (1.2 mg/kg). The dose stabilization phase was then
followed by a 20-week linear dose reduction phase. The client was dosed twice per week
at the treatment-research clinic, with “take home” doses provided for the intervening
days. This client’s initial dose was 120 mg. Some flexibility in the dose reduction
schedule was permitted to accommodate severe withdrawal and medical concerns. For
example, the client’s dose was held steady for an extra week in the last month of the
detoxification due to an increase in blood pressure.
Acceptance and Commitment Therapy
The present ACT protocol was largely drawn from existing ACT manuals (e.g.,
Hayes et al., 1999) and the previous ACT project on polysubstance use (Hayes, Wilson,
et al., 2004) (see Table 1). Modifications were made to reflect issues specific to
methadone detoxification. The ACT protocol consisted of 24 50-minute sessions
delivered weekly beginning in the stabilization period and continuing through the dose
reduction period. Each session typically started with a 5 to 10 minute mindfulness
exercise (e.g., breathing, sitting still, noticing and observing thoughts, feelings, bodily
sensations). Session specific components were introduced using the client’s personal
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experiences related to the methadone dose reduction and/or other life events.
Implementation and rationale for the four overarching ACT intervention components are
described generally in Table 1 and more specifically below.
--------------------------------------------------------------------------------------Insert Table 1 here
--------------------------------------------------------------------------------------Values Clarification. In contrast with several ACT protocols, values-focused
interventions were introduced to the client early, prior to beginning the methadone dose
reduction, for several reasons. One reason was to firmly establish ACT congruent
treatment goals and therapeutic rationale. Clarifying the client’s personal values gave the
therapy an overarching purpose based on what the client deemed most important.
Methadone detoxification itself was not the end-goal, but a step in the direction of a less
constricted and ultimately more meaningful life. Second, values-clarification was
introduced during the stabilization period to increase the client’s motivation and
commitment to enter into methadone detoxification. Finally, the client’s expected
trajectory of emotional and physiological distresses throughout the course of methadone
detoxification was taken into account for the timing of value-focused interventions.
Greater emotional and physiological distress was expected as his dose was decreased.
Strengthening personal values early in the treatment was thought to increase the
probability of program completion.
Linking the costs of previous and current substance use (and associated shame
and guilt) with personal values was extremely powerful in the value-focused phase. For
example, the client reported that the loss of his first wife was a most difficult and painful
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experience for him (e.g., strong sense of guilt for introducing her to heroin). When the
client emotionally disclosed his pain from the loss, the therapist gently said to the client:
“It seems like you have this pain and guilt because you cared about her. You
cared about intimacy, family, and trust. You still do. These are very important to
you. There are values under the pain and guilt. Perhaps you are about to start
methadone detox for this”.
The client was well-connected to the perspective and reported his willingness to commit
to methadone detoxification in order to have a value-directed life.
Shifting Perspectives. Sessions 5 through 9 primarily focused on shifting
perspectives from avoiding and controlling aversive private events (i.e., detoxification
fear, feelings of uncertainty, fear of failure, physical withdrawal experience) to letting go
of struggles (e.g., psychological acceptance). This was one of the most challenging tasks
for the client. He seemed to believe, as most people do, that negative private experiences
were likely to prevent him from staying committed to value-directed activities, including
methadone detoxification. Given this belief, he tried not to have these events by engaging
in distraction and positive self-talk (e.g., “I’ll be OK and stay positive!”), which seemed
quite logical. However, these strategies were highly unlikely to help him through the
detoxification process because distressing private experiences were simply inevitable.
Further, avoidance and control strategies and their failure to alleviate suffering were
likely to make these events worse, jeopardizing detoxification success. The only way to
ultimately control the physical symptoms of withdrawal is to use methadone or heroin
again. With this conceptualization, it was extremely crucial for the client to have the shift
in perspective.
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We found it helpful to suggest to the client that anxiety, depression, and physical
withdrawal symptoms are expected given his history and that these experiences do not
have the power to lead to the premature termination of detoxification or relapse to heroin.
After several sessions with this focus, the client began freely admitting and sharing his
feelings with the therapist and became open to an alternative to distraction and positive
self-talk.
Acceptance and Mindfulness. The stance of acceptance and mindfulness was
introduced to the client midway through the dose-reduction schedule as the client was
experiencing detoxification fears and subjective withdrawal symptoms at this time, but
not to a severe degree. For this client, more frequent voicing of his withdrawal
symptoms (sleeplessness, leg pain, upset stomach, etc) was considered an indication of
increased psychological acceptance, relative to his previous attempts to avoid all
discussion of such experiences.
In addition to using conventional ACT metaphors and experiential exercises (see
Hayes et al, 1999), we found that the phrases “I am having the thought that…” and “I am
noticing that ...” were useful to create distance from and reduce the attachment to his
distressing thoughts and feelings. These techniques helped to increase the client’s
psychological openness and nonjudgmental stance toward these private events. The client
learned experientially that withdrawal symptoms and negative affect did not
automatically lead him to substance use or premature discontinuation of therapy.
Commitment to Value-Directed Life. Sessions 18 through 24 focused on
maintaining an ongoing commitment to value-directed actions, including methadone dose
reduction. By week 18 of the therapy, the reduced dose of methadone resulted in highly
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distressing withdrawal symptoms (e.g., bone pain, nausea, sweating, insomnia). The
client’s experience of psychological and physical struggles (e.g., uncertainty, fear, pain)
were identified, validated and normalized, and put into context with the aspects of life he
found most important (i.e., values). Personal values were revisited, including his
commitment to finishing the program, to strengthen value-directed activities. Clientinitiated value congruent actions (e.g., calling his biological son) were especially
reinforced. In session 23 and 24, the client continued to report the gradually intensified
experience of withdrawal symptoms. Nevertheless, he also continued to report his
commitment to methadone detoxification and progress in communicating with his wife,
stepdaughters, and biological children, a self-identified target behavior. In the last session,
progress in treatment and plan for his future were discussed, and the individual therapy
session was terminated.
At the one-month follow-up, the client reported he was doing well, with only a
few residual withdrawal symptoms, mainly insomnia. At one year, he and his 2nd wife
were in the process of divorcing. He reported increased anxiety related to this situation,
but overall, he reported functioning well.
Results
Withdrawal Symptoms and Negative Affect. At intake, the client’s methadone dose
remained stable at 120 mg, yet his SOWS score indicated moderate degrees of
perspiration, teary eyes, running nose, and hot flushes and mild degrees of muscle aches
(see Figure 1). Throughout the course of the 24-week methadone dose reduction program,
his SOWS scores did not exceed pretreatment levels, despite fluctuation (i.e., ranging
from 1 to 13). During the second half of program, his SOWS scores indicated the
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presence of moderate stomach cramps, running nose, and anxiety. At the one-month
follow-up, the client reported no subjective withdrawal symptoms in the SOWS.
--------------------------------------------------------------------------------------Insert Figure 1 here
--------------------------------------------------------------------------------------The client’s BDI-II score was slightly increased at the one-month follow-up
relative to that of baseline (BDI-II = 15). The client endorsed some physiological
symptoms of depression that overlapped with the withdrawal symptoms of methadone,
such as fatigue and difficulty in sleeping. Increased negative affect at post-detoxificaion
is commonly reported and often associated with relapse to opiate use (e.g., McLellan,
Childress, Ehrman, O’Brien, & Pashko, 1986). In the midst of divorce process, he scored
17 on BDI-II at a one-year follow-up. He endorsed past failure, loss of pleasure, and loss
of sexual interest.
The client’s DFSS scores at the various time points were low relative to the cutoff score of 70 set by Milby and colleagues. Thus, although fear was reported, the client
is not part of the minority of MM clients who report diagnostically severe detoxification
phobia. Visual inspection of the data also indicates the client’s levels of detoxification
fears fluctuated over time, ranging from 10 to 20 (see Figure 1).
Psychological Inflexibility. The client’s AAQ-9 score at pretreatment (= 44) fell
within the upper quartile (AAQ-9 > 41; Hayes, Strosahl, et al., 2004) of PI among clinical
populations. A reduction was observed in week 4 (=38) and scores fluctuated between 40
and 35 throughout the course of dose reduction. His average AAQ-9 score during the
program was 38. The client scored 37 at the one-month follow-up and his AAQ at the

ACT for Methadone Detoxification

17

one-year follow-up was 36. Throughout the study, his score did not go below the mean of
non-Caucasian, non-clinical population (= 34.5).
Substance Use. Urine drug screen data revealed that the client was highly
successful in the methadone detoxification program. No use of any substances (i.e.,
cocaine, opiates, benzodiazepines, stimulants, or psychedelics) was found during the
entire 24-week program nor at the one-month follow-up, despite significant withdrawal
symptoms. Once his methadone dose reached zero, urine data indicated that methadone
was no longer present. The breath samples revealed continued abstinence from alcohol.
These findings were also consistent with his self-report collected during the course of the
program. At the one-year follow-up assessment, the client still remained opiate-free, yet
reported use of prescribed benzodiazepines which was confirmed by the urine screen.
Discussion
Growing evidence suggests a significant impact of emotional and cognitive
processes on substance use (Marlatt & Gordon, 1985) and the potential utility of
acceptance-based intervention for substance-related problems (Hayes, Wilson, et al.,
2004). The present investigation reports on the first client enrolled in a treatment
development study designed to examine the utility of ACT-based treatment for
methadone detoxification. Positive findings indicate that, despite the well-documented
odds against successful methadone detoxification, the client completed the program
without relapsing to illicit substances, maintained abstinence from all substances at onemonth follow-up, and remained opiate-free one year post-treatment.
Particularly of relevant for ACT are the elevated subjective withdrawal symptoms
reported at intake—an entire 4 weeks before the first reduction in dose. These data
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underscore the significance of the client’s anticipation and fear of withdrawal and other
unpleasant detoxification experiences which manifest as anxiety-related physical
symptoms. The presence of detoxification fear was also corroborated by a higher score at
intake on the DFSS relative to other time points. These variables fluctuated throughout
the course of methadone detoxification and at follow-up points, and do not seem to have
systematic relations to substance use outcomes.
A primary target in the ACT model is the way in which a client approaches
difficult private events, not these events. ACT is designed to increase client’s willing to
be open to difficult private events, while increasing value-based actions, collectively
referred to as psychological flexibility. Although the present case report did not clearly
show significant reduction in psychological inflexibility (PI), small changes in the
expected direction were noted. Future methadone detoxification studies should further
explore the role of PI on detoxification fears, subjective withdrawal symptoms, and
substance use outcomes.
It may seem surprising that the client chose to use benzodiazepines reportedly due
to emotional distress around the time of the one-year follow-up. This result could be
viewed as a failure of the ACT treatment or its durability, which of course are valid
hypotheses. However, the benzodiazepine use must be viewed within the context of the
typical methadone detoxification course and the client’s substance use history. First, the
success rates for methadone detoxification are dismal at best. Most studies report high
drop-out rates, with few patients achieving abstinence (~ 25%; Hall 1984). Some studies
have documented that all subjects returned to methadone or other opiate use during or in
the month following treatment (Grabowski et al., 2005). Second, this client has used
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substances his entire life since adolescence to cope with the inevitable and difficult
experiences of life. He used almost every class of drug available and became
physiologically dependent at different times on alcohol and heroin. Within this context,
the fact that the client went to a doctor and acquired a prescription for an anti-anxiety
medication (a behavior engaged in by many Americans), versus returning to opiates or
other illicit drugs, can arguably be viewed as responsible behavior in the context of a
distressing environmental situation (divorce)—a significant accomplishment for this
client. Of course, if the client used the medication such that it began to interfere with
pursing important life values, then the durability of ACT may be questioned and the need
for booster sessions may be entertained. If the client uses benzodiazepines for a period of
time without negative consequences in other life domains, however, we would not
consider him a treatment failure.
Methodologically, it should be noted that although reductions in PI were found
using the general, non-problem-specific AAQ, the decrements were not large. Failure to
find large changes on the general AAQ has been reported in other studies as well (e.g.,
Hayes et al., 2006). A measure of psychological inflexibility related to the experience of
methadone detoxification may more precisely capture the specific fears and avoidance
strategies typical of the population. Future research is needed to develop and test such a
measure.
It is important to note that there are competing explanations for treatment success.
The first factor is simply age. The client was 57 years old, and based on the typical
course of substance abuse, he was more likely to achieve abstinence from drugs
compared to substance users in younger age groups. It is important to note, however, that
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he failed detoxification twice in very recent years, and that many other clients in our
substance abuse clinic of similar age have not succeeded to this level. Another factor that
could influence treatment outcome is the dose-reduction schedule. The duration of the
preset dose reduction program (i.e., 24 weeks) was longer than those used in most
previous studies (e.g., 3, 6, or 12 weeks). Positive results in the present case might be
simply due to the longer period of gradual dose reduction. Perhaps even more importantly
is that this client was abstinent from all other substances upon commencing the
detoxification program. This is not the norm in the methadone-using population and may
have played a large role in his ability to achieve and maintain opiate abstinence.
Thus, further study with methodological rigor is needed to determine whether the
ACT-enhanced methadone dose reduction is effective for more complicated MM clients.
Exploration of client characteristics indicative of success with the ACT-based treatment
also seems warranted, particularly examining the relation between PI and treatment
outcomes. Given the results of the present case study, it seems worthwhile to continue
research on this promising behavioral therapy for the methadone-using population.
Finally, it is important to acknowledge that methadone dose reduction is
extremely complicated. The physical and psychological distress experienced by these
clients should not be underestimated. Although there is much research to be done to
determine the conditions under which clients will benefit from methadone detoxification,
the present case suggests that there are MM clients who can successfully detoxify and
lead drug-free lives. Researchers have an obligation to better understand the process in
order to develop more precisely focused and effective treatments.

ACT for Methadone Detoxification

21

References
Amato, L., Davoli, M., Ferri, M., Gowing, L., & Perucci, C. A. (2004). Effectiveness of
interventions on opiate withdrawal treatment: An overview of systematic reviews.
Drug and Alcohol Dependence, 73, 219-226.
Beck, A. T. (1996). Beck depression inventory (2nd ed.). San Antonio, TX; The
Psychological Corporation.
Brown, R. A., Palm, K. M., Strong, D. R., Lejuez, C. W., Kahler, C. W., Zvolensky, M. J.
et al. (2008). Distress tolerance treatment for early-lapse smokers: Rationale,
program description, and preliminary findings. Behavior Modification, 32, 302332.
Berger, H., & Schweger, M. J. (1973). Voluntary detoxification of clients on methadone
maintenance. The International Journal of the Addictions, 6, 1045-1047.
Compton, P., Charuvastra, V. C., & Ling, W. (2001). Pain intolerance in opioidmaintained former opiate addicts: Effect of long-acting maintenance agent. Drug
and Alcohol Dependence, 63, 139-146.
D’Aunno, T. D., Folz-Murphy, N., & Lin, X. (1999). Changes in methadone treatment
practices: Results from a panel study, 1988-1995. American Journal of Drug and
Alcohol Abuse, 25, 681-699.
Eklund, C., Hiltunen, A. J., Melin, L., & Borg, S. (1997). Abstinence fear in methadone
maintenance withdrawal: A possible obstacle for getting off methadone.
Substance Use & Misuse, 32, 779-792.
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2002). Structured Clinical
Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition.

ACT for Methadone Detoxification

22

(SCID-I/P). New York; Biometrics Research, New York State Psychiatric
Institute.
Gentile, M. A., & Milby, J. B. (1992). Methadone maintenance detoxification fear: A
study of its components. Journal of Clinical Psychology, 48, 797-807.
Gifford, E. V., Kohlenberg, B. S., Hayes, S. C., Antonuccio, D. O., Piasecki, M. M.,
Rasmussen-Hall, M. L., et al. (2004). Acceptance theory-based treatment for
smoking cessation: An initial trial of acceptance and commitment therapy.
Behavior Therapy, 35, 689-706.
Gossop, M. (1990). The development of a subjective opiate withdrawal scale. Addictive
Behaviors, 15, 487-490.
Gossop, M., Marsden, J., Stewart, D., & Treacy, S. (2001). Outcomes after methadone
maintenance and methadone reduction treatments: two-year follow-up results
from the National Treatment Outcome Research Study. Drug and Alcohol
Dependence, 62, 255-264.
Gossop, M., & Strange, I. (1991). A comparison of the withdrawal responses of heroin
and methadone addicts during detoxification. British Journal of Psychiatry, 158,
697-699.
Grabowski, J., Moeller, F., Dougherty, A., Stotts, A., Garcia, A., McQueen, K. et al.
(2005, June). Optimal dosing strategies in opioid maintenance. Poster presented
at the 67th Annual Scientific Meeting of the College on Problems of Drug
Dependence. Orlando, FL.
Hall, S. M. (1984). The abstinence phobias: links between substance abuse and anxiety.
International Journal on Addiction, 19, 613-31.

ACT for Methadone Detoxification

23

Handelsman, L., Cochrane K. L., Aronson, M. J., Ness, R., Rubinstein, K. J., & Kanof, P.
D (1987). Two new rating scales for opiate withdrawal. American Journal of
Drug and Alcohol Abuse, 13, 293-308.
Hayes, S. C., Strosahl, K., & Wilson, K. G. (1999). Acceptance and Commitment
Therapy: An experiential approach to behavior change. New York: The Guilford
Press.
Hayes, S. C., Strosahl, K. D., Wilson, K. G., Bissett, R. T., Pistorello, J., Toarmino, D., et
al. (2004). Measuring experiential avoidance: A preliminary test of a working
model. The Psychological Record, 54, 553-578.
Hayes, S. C., Wilson, K. G., Gifford, E., Bissett, R., Batten, S., Piasecki, M., et al.
(2004). A preliminary trial of Twelve-Step Facilitation and Acceptance and
Commitment Therapy with poly substance-abusing methadone-maintained opiate
addicts. Behavior Therapy, 35, 667-688.
Heffner, M., Eifert, G. H., Parker, B. T., Hernandesz, D. H., & Sperry, J. A. (2003).
Valued directions: Acceptance and Commitment Therapy in the treatment of
alcohol dependence. Cognitive and Behavioral Practice, 10, 378-383.
Hollands, G. B. & Turecek, J. R. (1980). An evaluation of behaviour therapy programme
as an intervention treatment for the fear of withdrawal with heroin-dependent
persons. Drug and Alcohol Dependence, 5, 153-160.
Latowsky, M. (1996). Improving detoxification outcomes from methadone maintenance
treatment: The interrelationship of affective states and protracted withdrawal.
Journal of Psychoactive Drugs, 28, 251-257.

ACT for Methadone Detoxification

24

Lejuez, C. W., Paulson, A., Daughters, S. B., Bornovalova, M. A., & Zvolensky, M. J.
(2006). The association between heroin use and anxiety sensitivity among innercity individuals in residential drug use treatment. Behaviour Research and
Therapy, 44, 667-677.
Lenne, M., Lintzeris, N., Breen, C., Harris, S., Hawken, L., Mattick, R., et al. (2001).
Withdrawal from methadone maintenance treatment: prognosis and participant
perspectives. Australian and New Zealand Journal of Public Health, 25, 121-125.
Magura, S., & Rosenblum, A. (2001). Leaving methadone treatment: Lessons learned,
lessons forgotten, lesson ignored. The Mount Sinai Journal of Medicine, 68, 6274.
Marlatt, G. A., & Cordon, J. R. (1985). Relapse prevention. New York: Guilford Press
McLellan, A.T., Childress, A.R., Ehrman, R., O’Brien, & Pashko, S. (1986).
Extinguishing conditioned responses during opiate dependence treatment:
Turning laboratory findings into clinical procedures. Journal of Substance
Treatment, 3, 33-40.
McLellan A. T., Luborsky L., Woody G. E., & O’Brien C. P. (1980). An improved
diagnostic evaluation instrument for substance abuse patients. Journal of Nervous
and Mental Disease, 168, 26-33.
Milby, J. B., Hohmann, A. A., Gentile, M., Huggins, N., Sims, M. K., McLellan, T., et al.
(1994). Methadone maintenance outcome as a function of detoxification phobia.
American Journal of Psychiatry, 151, 1031-1037.

ACT for Methadone Detoxification

25

Robles, E., Stitzer, M. L., Strain, E. C., Bigelow, G. E., & Silverman, K. (2002).
Voucher-based reinforcement of opiate abstinence during methadone
detoxification. Drug and Alcohol Dependence, 65, 179-189.
Simpson, D. D., Joe, G. W., & Bracy, S. A. (1982). Six-year follow-up of opioid addicts
after admission to treatment. Archives of General Psychiatry, 39, 1318-1323.
Twohig, M. P., Shoenberger, D., & Hayes, S. C. (2007). A preliminary investigation of
Acceptance and Commitment Therapy as a treatment for marijuana dependence in
adults. Journal of Applied Behavior Analysis, 40, 619-632.

ACT for Methadone Detoxification

26

Table 1. Overview of ACT Components and Strategies
Sessions
1-4

Components/Strategies
• Rapport Building

Goals/Purposes
• Client and therapist develop ACT-consistent treatment
alliances and goals.

• Choosing a valued
direction (value
clarification)

• Client identifies values and increases motivation for
having a value-directed life as well as commitment to
methadone detoxification.

• Shifting Perspective:
Control is the problem

• Client identifies his previous and current coping styles
for difficult psychological events (e.g., anxiety, selfdoubt, fear, negative bodily sensation, etc).
• Client learns these coping strategies are for controlling
and avoiding negative psychological events.
• Client learns that these coping strategies are not
working well in the long run.
• Client explores ways in which control and avoidance
attempts prevent him from engaging in value-directed
behaviors.
• Attempts to control and avoid problematic private
events might have negative iatrogenic effects.

• Letting go of struggle

• Client notices the futility of control and avoidance
attempts and is willing to consider an alternative
approach to his difficult private events (e.g., fear of
uncertainty, fear of failure).

10-18

• Acceptance and
Mindfulness

• Client learns psychological acceptance as an
alternative to avoidance and control attempts.
• Client chooses to be open to or to allow whatever he is
experiencing as it is (i.e., acceptance), even difficult
psychological events.
• Client learns to observe his private events.
• Client learns not to get sidetracked by his difficult
psychological events.

19-24

• Commitment

• Client progresses toward a committed and valuedirected life (e.g., the completion of methadone
detoxification).

5-9
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Figure Caption
Figure 1. Methadone dose schedule, subjective opiates withdrawal experiences,
detoxification fear, and psychological inflexibility throughout the course of ACTenhanced methadone detoxification program.
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